公开(公告)号：US20180028516A1

公开(公告)日：2018-02-01

申请号：US15454636

申请日：2017-03-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/26 ,  A61K9/00 ,  A61K9/10 ,  A61M37/00 ,  A61K47/38 ,  A61K47/12 ,  A61K45/06 ,  A61K31/573 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20170333416A1

公开(公告)日：2017-11-23

申请号：US15673073

申请日：2017-08-09

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  C07K16/22 ,  A61K9/16 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20220249517A1

公开(公告)日：2022-08-11

申请号：US17478112

申请日：2021-09-17

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Daniel WHITE ,  Glenn NORONHA ,  Jennifer KISSNER

IPC: A61K31/58 ,  A61K9/00 ,  A61P27/02 ,  A61M37/00 ,  A61K47/02 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  A61K47/38

Abstract: The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.

公开(公告)号：US20180325884A1

公开(公告)日：2018-11-15

申请号：US16041067

申请日：2018-07-20

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  C07K16/22 ,  A61K47/38 ,  A61K9/00 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61M37/00 ,  A61K47/26 ,  A61K47/12 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20160206628A1

公开(公告)日：2016-07-21

申请号：US15001610

申请日：2016-01-20

Applicant: Clearside Biomedical, Inc.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/573 ,  A61K47/12 ,  A61K47/26 ,  A61K9/00 ,  A61K47/38

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20190269702A1

公开(公告)日：2019-09-05

申请号：US16292845

申请日：2019-03-05

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Daniel WHITE ,  Glenn NORONHA ,  Jennifer KISSNER

IPC: A61K31/58 ,  A61K9/00 ,  A61P27/02 ,  A61M37/00

Abstract: The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.

公开(公告)号：US20190240208A1

公开(公告)日：2019-08-08

申请号：US16124407

申请日：2018-09-07

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K47/26 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K45/06 ,  A61K47/12 ,  A61M37/00 ,  A61K9/16 ,  C07K16/22 ,  A61K31/573

CPC classification number: A61K31/4439 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/10 ,  A61K9/16 ,  A61K31/573 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/38 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2300/00 ,  A61M37/0015 ,  A61M2037/0023 ,  A61M2037/0061 ,  C07K16/22

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20180042765A1

公开(公告)日：2018-02-15

申请号：US15319045

申请日：2015-06-17

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Glenn NORONHA ,  Christopher John BROOKS ,  Rafael Victor ANDINO ,  Samirkumar PATEL ,  Daniel WHITE

IPC: A61F9/00

CPC classification number: A61F9/0008 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/573 ,  A61K47/38

Abstract: The present invention relates to a methods and devices for treating uveitis, macular edema associated with uveitis and macular edema associated with retinal vein occlusion in a human subject in need thereof. In certain aspects, devices provided herein include a medicament container defining a lumen configured to contain a medicament, a distal end portion of the medicament container including a coupling portion configured to be removably coupled to a needle assembly, a proximal end portion of the medicament container including a flange and a longitudinal shoulder; a piston assembly including a distal end portion movably disposed within the lumen of the medicament container; and a handle coupled to a proximal end portion of the piston assembly.

公开(公告)号：US20210260047A1

公开(公告)日：2021-08-26

申请号：US17314272

申请日：2021-05-07

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Vladimir ZARNITSYN ,  Samirkumar PATEL ,  Daniel WHITE ,  Glenn NORONHA ,  Brian BURKE

IPC: A61K31/4439 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K45/06 ,  C07K16/22 ,  A61K31/573 ,  A61K9/16 ,  A61M37/00 ,  A61K47/12 ,  A61K47/26

Abstract: Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.

公开(公告)号：US20190133933A1

公开(公告)日：2019-05-09

申请号：US16097303

申请日：2017-05-01

Applicant: CLEARSIDE BIOMEDICAL, INC.

Inventor： Richard BECKMAN ,  Jesse YOO ,  Rafael Victor ANDINO ,  Glenn NORONHA ,  Samirkumar PATEL ,  Donna TARABORELLI ,  Vladimir ZARNITSYN

IPC: A61K9/00 ,  A61K47/36 ,  A61F9/00 ,  A61F9/007 ,  A61M37/00

Abstract: The current disclosure relates to formulations and methods for reducing intraocular pressure (IOP) in the eye of a subject in need thereof. The disclosure also relates to formulations and methods for reducing intraocular pressure (IOP) related to glaucoma in a subject. The methods provided include non-surgically administering a non-pharmacologically active injectable formulation to the eye of the subject by using an apparatus that is suitable for delivering the formulations. The methods provided also include placing a solid implant into the eye of the subject to create a controlled space in the suprachoroidal space (SCS) or the supraciliary space of the eye of the subject in need thereof. The present disclosure further comprises facilitating and improving the aqueous outflows in the eye through the trabecular meshwork outflow pathway and/or uveoscleral outflow pathway and thereby decreasing the intraocular pressure.